Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Authors' conclusion
Empagliflozin is effective in reducing liver fat content in individuals with and without T2D. The decrease in liver fat content is independent of the decrease in plasma glucose concentration and is strongly related to the decrease in body weight and improvement in insulin sensitivity.
Study context
- Population
- Individuals with T2D and without T2D30 with T2D, 27 without · Individuals with T2D 30 · without T2D 27
- Comparison
- Empagliflozin vs placebo for 12 weeks
- Primary endpoint
- Change in liver fat content measured with MRS
- Follow-up
- 12 weeks
Methodological detailsdouble-blind, placebo-controlled, randomized 2:1
- Double-blind
- Placebo-controlled
- Randomized 2:1
Primary result
As reported in the abstract
Change in liver fat content
Empagliflozin
2.39%
± 0.79%
Placebo
0.91%
± 0.64%
P < 0.007 with ANOVA
Further findings
| Outcome | With diabetes | Without diabetes | P value |
|---|---|---|---|
| Decrease in liver fat with empagliflozin, by diabetes statusComparable | 2.75% ± 0.81% | 1.93% ± 0.78% | P = NS |
Correlates of liver fat decrease with empagliflozin
- Correlation with baseline liver fat content (P < 0.001)
- r = −0.62
- Correlation with decrease in body weight (P < 0.001)
- r = 0.53
- Correlation with improvement in insulin sensitivity (P < 0.001)
- r = −0.51
- Not related to decrease in FPG or HbA1c or increase in hepatic glucose production
Original publication
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes Care. Published 31 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →